Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in Covaxin

Govt Panel Recommends Corbevax As Booster Dose For Adults

The COVID-19 Working Group (CWG), in its July 20 meeting, reviewed data of the double-blind randomized phase-3 clinical study which evaluated the immunogenicity and safety of booster dose of Corbevax vaccine when administered to COVID-19-negative adult volunteers of age 18-80 years previously vaccinated with two doses of either Covishield or Covaxin.

Read More

Covaxin Proven Safe For Children Of 2-18 Years Age Group In Phase III Study: Bharat Biotech

Bharat Biotech said in the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within one day. Pain at the injection site was the most commonly reported adverse event

Read More

Covaxin Shows Robust Safety & Immunogenicity In Children 2-18 Years

Bharat Biotech International Limited (BBIL), a global developer of vaccines for infectious diseases, today announced that BBV152 (COVAXINÒ), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study.

Read More

Covaxin's Clinical Trials Can Resume In US As FDA Lifts Hold

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation's observations on Covaxin manufacturing plants in India

Read More

Covaxin Gets Emergency Use Authorisation For Children Aged 6-12: Sources

The development comes after the Subject Expert Committee (SEC) of the DCGI asked Bharat Biotech for additional data on Covaxin, for administering it to children aged between 2-12 years, sources said

Read More

Covaxin Booster Amplifies Protection Against Variants Of Concern: ICMR Study

As a part of the study the antibody responses in sera of 51 participants who received two doses of Covaxin collected six months post second dose and 28 days after receiving a third (booster) dose (given on day 215th post second dose) and its impact against the Omicron VoC was evaluated

Read More

Covishield And Covaxin Doses To Cost Rs 225 Now In Private Hospitals

The Serum Institute of India has cut the rates of Covishield from ₹600 to ₹225 per dose, while Bharat Biotech has brought down the price of Covaxin from ₹1,200 to ₹225

Read More

India's Expert Panel Advises Full Approval For Covishield, Covaxin

Covaxin and Covishield received emergency use authorisation in India in January 2021, with more than a combined 1.5 billion doses having been administered so far, according to government data.

Read More

Govt Expert Panel Recommends Regular Market Approval For Covishield, Covaxin

Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.

Read More

Covaxin Shows 50% Effectiveness Against Symptomatic COVID-19 In Real-World Assessment: Lancet Study

The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees.

Read More

Covaxin 77.8% Effective Against COVID-19: Lancet Study

The efficacy analysis demonstrated that Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19.

Read More

WHO Approval To Covaxin Will Improve Ease Of Travel For Vaccinated Indians: MEA

MEA Spokesperson Arindam Bagchi said 96 countries have either accepted WHO-approved vaccines, which would include both Covishield and Covaxin, or in some cases only Covishield or Covaxin.

Read More

UK To Add India's Covaxin To Approved Vaccine List For Inbound Travellers

The move follows the World Health Organisation's (WHO) Emergency Use Listing for Covaxin, which is the second most used formulation in India.

Read More

Bharat Biotech's Partner Ocugen Files EUA Request With FDA For Paediatric Use Of Covaxin

Having a new type of vaccine available will enable people to discuss with their child's physician the best approach for them to lower their child's risk of contracting COVID-19

Read More

Bharat Biotech To Produce 700 Mn Covaxin Doses Annually

According to a press release issued by the Hyderabad-based vaccine maker, manufacturing scale-up has been carried out in a stepwise manner across multiple facilities at Hyderabad and Bangalore.

Read More